Citadel Advisors’s Spyre Therapeutics SYRE Stock Holding History

Citadel Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$772K	Sell	15,300 -9,600	-39%	-$362K	﹤0.01%	8278
2025 Q4	$816K	Buy	+24,900	New	+$651K	﹤0.01%	7866
2025 Q2	–	Sell	-6,100	Closed	-$98.4K	–	15015
2025 Q1	$98.4K	Buy	6,100 +2,700	+79%	+$56.2K	﹤0.01%	11491
2024 Q4	$79.2K	Buy	3,400 +2,100	+162%	+$61.6K	﹤0.01%	11802
2024 Q3	$38.2K	Sell	1,300 -200	-13%	-$5.57K	﹤0.01%	12188
2024 Q2	$35.3K	Buy	+1,500	New	+$50.6K	﹤0.01%	12114
2024 Q1	–	Sell	-4	Closed	-$86	–	15418
2023 Q4	$86	Hold	4	–	–	﹤0.01%	14138
2023 Q3	$49	Buy	+4	New	+$53	﹤0.01%	14183
2021 Q1	–	Sell	-2,800	Closed	-$551K	–	13700
2020 Q4	$551K	Buy	+2,800	New	+$580K	﹤0.01%	7955

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Citadel Advisors's SYRE Position: Q1 2026 in Review

Citadel Advisors increased its Spyre Therapeutics (SYRE) stake by 69% in Q1 2026, buying an estimated $1.67M and bringing the position to 108,135 shares worth $5.45M. The position accounts for ﹤0.01% of the portfolio, ranked #4206.

Citadel Advisors first reported a position in SYRE in Q2 2016 and has held it in 21 quarters since. The position peaked at $26.8M in Q1 2024. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

Citadel Advisors held 108,135 shares of Spyre Therapeutics worth $5.45M as of Q1 2026.
Citadel Advisors bought 44,231 Spyre Therapeutics shares in Q1 2026, an estimated $1.67M.
Spyre Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4206 holding.
Citadel Advisors first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 21 quarters since.
Citadel Advisors's Spyre Therapeutics position peaked at $26.8M in Q1 2024.
197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.